Osteolabs GmbH has closed its first commercial agreements for Germany and Turkey. For Germany, the company has signed up with Eurofins LifeCodexx GmbH as exclusive partner in the field of gynecology for the commercialization of its novel diagnostic test for early detection of osteoporosis. Eurofins LifeCodexx became a market leader in this gynecology segment over the last couple of years as first provider of PraenaTest, a non-invasive prenatal testing method (NIPT) for detection of fetal trisomies from maternal blood. For Turkey, a similar commercial agreement has been signed with BioGen Medical, a leading distributor for laboratory developed tests.
 
In addition, the Osteolabs test will be used in a comprehensive contract research collaboration with the Health Department of an European Army over the course of 3 years. During that time, over 1,000 tests will be performed to determine the correlation of calcium depletion with intense physical activities and bone fractures in female military staff. The application of the osteoporosis test should allow to further validate the potential of the test for early detection of calcium depletion from the skeleton which could be further used for therapeutic monitoring of osteoporosis medications.
 
During the recent opening of its new facilities, Stefan Kloth, managing director, Osteolabs GmbH, said, “We are extremely pleased with the company developments since our first financing round closing in summer 2019. With the first two commercial agreements we will be in a good position in Germany and Turkey to accelerate uptake of our novel testing method.”
 
Osteolab´s chief scientist, Anton Eisenhauer, said, “The joint research collaboration together is a strong recognition of the potential of our novel testing method for osteoporosis. With this collaboration we intend to examine whether female military staff experience health issues from calcium depletion as an imbalance in calcium supply may lead to bone fractures even at younger age.”